Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma: Results From at Least 1-Year Follow-Up in all Patients

被引：0
|
作者：
Frigault, Matthew [1 ]
Rosenblatt, Jacalyn [2 ]
Dhakal, Binod [3 ]
Raje, Noopur [4 ]
Cook, Daniella [1 ]
Gaballa, Mahmoud [5 ]
Emmanuel-Alejandro, Estelle [2 ]
Nissen, Danielle [3 ]
Banerjee, Kamalika [6 ]
Rotte, Anand [6 ]
Heery, Christopher [6 ]
Avigan, David [2 ]
Jakubowiak, Andrzej [7 ]
Bishop, Michael [7 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Arcellx Inc, Redwood City, CA USA
[7] Univ Chicago, Chicago, IL 60637 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
MM; multiple myeloma; BCMA; plasma cell; anitocabtagene autoleucel;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-364
引用
收藏
页码：S553 / S553
页数：1
相关论文
共 50 条
  • [1] Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort
    Ri, Masaki
    Suzuki, Kenshi
    Ishida, Tadao
    Kuroda, Junya
    Tsukamoto, Taku
    Teshima, Takanori
    Goto, Hideki
    Jackson, Carolyn C.
    Sun, Huabin
    Pacaud, Lida
    Fujikawa, Ei
    Yeh, Tzu-Min
    Hatayama, Tomoyoshi
    Aida, Kensuke
    Sunagawa, Yoshihiro
    Iida, Shinsuke
    CANCER SCIENCE, 2022, 113 (12) : 4267 - 4276
  • [2] CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma
    Lin, Yi
    Martin, Thomas
    Usmani, Saad
    Berdeja, Jesus
    Jakubowiak, Andrzej
    Agha, Mounzer
    Cohen, Adam
    Deol, Abhinav
    Htut, Myo
    Lesokhin, Alexander
    Munshi, Nikhil
    O'Donnell, Elizabeth
    Jackson, Carolyn
    Yeh, Tzu-Min
    Banerjee, Arnob
    Zudaire, Enrique
    Madduri, Deepu
    delCorral, Christopher
    Pacaud, Lida
    Jagannath, Sundar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S488 - S489
  • [3] Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
    Garfall, Alfred L.
    Nooka, Ajay K.
    van de Donk, Niels W. C. J.
    Moreau, Philippe
    Bhutani, Manisha
    Oriol, Albert
    Martin, Thomas G.
    Rosinol, Laura
    Mateos, Maria-Victoria
    Bahlis, Nizar
    Popat, Rakesh
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Krishnan, Amrita Y.
    Delforge, Michel
    Huang, Lin
    Vishwamitra, Deeksha
    Stephenson, Tara
    Chastain, Katherine
    Sidana, Surbhi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S548 - S548
  • [4] iMMagine-3: A Phase 3, Randomized Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel (Anito- Cel) With Standard of Care in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
    Martin, Tom
    Raje, Noopur S.
    San Miguel, Jesus
    Patel, Krina
    Mcloughlin, Lucas
    Lui, Christine
    Jackson, Carolyn C.
    Heery, Christopher R.
    van de Donk, Niels W. C. J.
    Berdeja, Jesus G.
    Victoria Mateos, Maria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S554 - S555
  • [5] Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma
    Berdeja, Jesus G.
    Cohen, Adam D.
    Martin, Thomas
    Madduri, Deepu
    Pacaud, Lida
    Jagannath, Sundar
    FUTURE ONCOLOGY, 2023, 19 (18) : 1235 - 1247
  • [6] A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
    Watanabe, Takashi
    Tobinai, Kensei
    Matsumoto, Morio
    Suzuki, Kenshi
    Sunami, Kazutaka
    Ishida, Tadao
    Ando, Kiyoshi
    Chou, Takaaki
    Ozaki, Shuji
    Taniwaki, Masafumi
    Uike, Naokuni
    Shibayama, Hirohiko
    Hatake, Kiyohiko
    Izutsu, Koji
    Ishikawa, Takayuki
    Shumiya, Yoshihisa
    Kashihara, Tomohisa
    Iida, Shinsuke
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (05) : 745 - 756
  • [7] Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation
    Schneidawind, Corina
    Duerr-Stoerzer, Silke
    Faul, Christoph
    Kanz, Lothar
    Weisel, Katja
    Bethge, Wolfgang
    Schneidawind, Dominik
    CLINICAL TRANSPLANTATION, 2017, 31 (07)
  • [8] Predictors of Survival Outcomes in Phase 1 Relapsed or Refractory Multiple Myeloma Patients
    Barbee, Meagan S.
    Nooka, Ajay
    Kaufman, Jonathan L.
    Kim, Sungjin
    Chen, Zhengjia
    Heffner, Leonard T., Jr.
    Lonial, Sagar
    Harvey, R. Donald
    CANCER, 2015, 121 (06) : 853 - 862
  • [9] Updated follow-up of patients treated with bortezomib for relapsed multiple myeloma
    Santini, D.
    Vincenzi, B.
    Tonini, G.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (06): : 304 - 305
  • [10] Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study
    Iida, Shinsuke
    Watanabe, Takashi
    Matsumoto, Morio
    Suzuki, Kenshi
    Sunami, Kazutaka
    Ishida, Tadao
    Ando, Kiyoshi
    Chou, Takaaki
    Ozaki, Shuji
    Taniwaki, Masafumi
    Uike, Naokuni
    Shibayama, Hirohiko
    Hatake, Kiyohiko
    Izutsu, Koji
    Ishikawa, Takayuki
    Shumiya, Yoshihisa
    Tobinai, Kensei
    CANCER SCIENCE, 2019, 110 (09) : 2924 - 2932
12345